Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
The Lancet. Gastroenterology & Hepatology|February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority studyPietro Lampertico, Maria Buti, Scott Fung, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 2, 2022
Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis CCatrina M Loucks, Jennifer J Lin, Jessica N Trueman, et al.
JAMA|May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosisAndrew J Muir, Fred Poordad, Jacob Lalezari, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 27, 2022
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis BMan-Fung Yuen, Chi-Yi Chen, Chun-Jen Liu, et al.
Advances in Therapy|October 29, 2024
Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated CirrhosisMarkus Cornberg, Dietrich Hüppe, Christoph Sarrazin, et al.
Gastroenterology|October 15, 2014
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infectionGregory J Dore, Eric Lawitz, Christophe Hézode, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 23, 2018
Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV InfectionWai-Kay Seto, Yasuhiro Asahina, Todd T Brown, et al.
Viruses|December 23, 2022
Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA)Carla S Coffin, Sarah Haylock-Jacobs, Karen Doucette, et al.
CMAJ Open|October 24, 2019
Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV NetworkCarla S Coffin, Alnoor Ramji, Curtis L Cooper, et al.
JHEP Reports : Innovation in Hepatology|March 21, 2024
Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responsesMan-Fung Yuen, Scott Fung, Xiaoli Ma, et al.
Pageof 9